Search results for schering-plough
A few day ago, Schering-Plough ceo Fred Hassan appeared on CNBC's Mad Money, where he spoke with Jim Cramer, the hyperactive host, about the controversy surrounding Vytorin. In particular, Cramer as
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
The drugmaker, which is reeling from the controversy over Vytorin and the ensuing drop in prescriptions, is closing plants and cutting 10 percent of its workforce of 55,000 in order to save up to $1.
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Just a few days before eliminating more than 1,000 sales reps as part of a massive cost-cutting campaign designed to save $1.5 billion in expenses by 2012, the drugmaker awarded its chief scientist a
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS(TM) (asenapine) sublingual tablets in the ac
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Schering-Plough Corporation (NYSE: SGP) has announced the introduction of new CLARITIN(R) Liqui-Gels(R), the first and only non-drowsy allergy medicine in an easy-to-swallow liquid-filled capsule. No
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Schering-Plough Corporation (NYSE: SGP - News) has reported financial results for the 2008 fourth quarter and full year. "Schering-Plough delivered a very strong performance in 2008 - in the face of
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Schering-Plough announces an investment in early drug discovery technologies supporting Research and Development. Ultra High Throughput Screening (uHTS) capabilities will be established at the SPRI c
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Schering-Plough Corporation (NYSE: SGP) has announced a license agreement between Nobilon, Schering-Plough's human vaccine business unit, and the World Health Organization (WHO) to provide access to
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Scheri
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follic
read more »
1 Comment Add this link to... Bury
1 Comment Add this link to... Bury
« previous1 next »
